AstraZeneca : AstraZeneca nous offre quelques « easter eggs »
>Deux bonnes nouvelles qui renforcent notre investment case - Si nous avons déjà connu meilleur week-end de Pâques, confinement oblige, celui d’AstraZeneca fut très bon. La société a publié deux bonnes nouvelles : 1/ la levée d’aveugle 2 ans avant la date prévue d’une phase 3 de Tagrisso pour cause d’efficacité écrasante et 2/ l’autorisation aux US d’un nouveau produit, Koselugo (selumetinib), dans des tumeurs causées par une maladie rare, la neurofibromatose de type...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.